Cargando…

A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma

PURPOSE: Noninvasively assessing the tumor biology and microenvironment before treatment is greatly important, and glypican-3 (GPC-3) is a new-generation immunotherapy target for hepatocellular carcinoma (HCC). This study investigated the application value of a nomogram based on LI-RADS features, qu...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yan, Zhang, Yue-yue, Yu, Qin, Chen, Tong, Wei, Chao-gang, Zhang, Rui, Hu, Wei, Qian, Xu-jun, Zhu, Zhi, Zhang, Xue-wu, Shen, Jun-kang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941525/
https://www.ncbi.nlm.nih.gov/pubmed/36824129
http://dx.doi.org/10.3389/fonc.2023.1123141
_version_ 1784891302164299776
author Song, Yan
Zhang, Yue-yue
Yu, Qin
Chen, Tong
Wei, Chao-gang
Zhang, Rui
Hu, Wei
Qian, Xu-jun
Zhu, Zhi
Zhang, Xue-wu
Shen, Jun-kang
author_facet Song, Yan
Zhang, Yue-yue
Yu, Qin
Chen, Tong
Wei, Chao-gang
Zhang, Rui
Hu, Wei
Qian, Xu-jun
Zhu, Zhi
Zhang, Xue-wu
Shen, Jun-kang
author_sort Song, Yan
collection PubMed
description PURPOSE: Noninvasively assessing the tumor biology and microenvironment before treatment is greatly important, and glypican-3 (GPC-3) is a new-generation immunotherapy target for hepatocellular carcinoma (HCC). This study investigated the application value of a nomogram based on LI-RADS features, quantitative contrast-enhanced MRI parameters and clinical indicators in the noninvasive preoperative prediction of GPC-3 expression in HCC. METHODS AND MATERIALS: We retrospectively reviewed 127 patients with pathologically confirmed solitary HCC who underwent Gd-EOB-DTPA MRI examinations and related laboratory tests. Quantitative contrast-enhanced MRI parameters and clinical indicators were collected by an abdominal radiologist, and LI-RADS features were independently assessed and recorded by three trained intermediate- and senior-level radiologists. The pathological and immunohistochemical results of HCC were determined by two senior pathologists. All patients were divided into a training cohort (88 cases) and validation cohort (39 cases). Univariate analysis and multivariate logistic regression were performed to identify independent predictors of GPC-3 expression in HCC, and a nomogram model was established in the training cohort. The performance of the nomogram was assessed by the area under the receiver operating characteristic curve (AUC) and the calibration curve in the training cohort and validation cohort, respectively. RESULTS: Blood products in mass, nodule-in-nodule architecture, mosaic architecture, contrast enhancement ratio (CER), transition phase lesion-liver parenchyma signal ratio (TP-LNR), and serum ferritin (Fer) were independent predictors of GPC-3 expression, with odds ratios (ORs) of 5.437, 10.682, 5.477, 11.788, 0.028, and 1.005, respectively. Nomogram based on LI-RADS features (blood products in mass, nodule-in-nodule architecture and mosaic architecture), quantitative contrast-enhanced MRI parameters (CER and TP-LNR) and clinical indicators (Fer) for predicting GPC-3 expression in HCC was established successfully. The nomogram showed good discrimination (AUC of 0.925 in the training cohort and 0.908 in the validation cohort) and favorable calibration. The diagnostic sensitivity and specificity were 76.9% and 92.3% in the training cohort, 76.8% and 93.8% in the validation cohort respectively. CONCLUSION: The nomogram constructed from LI-RADS features, quantitative contrast-enhanced MRI parameters and clinical indicators has high application value, can accurately predict GPC-3 expression in HCC and may help noninvasively identify potential patients for GPC-3 immunotherapy.
format Online
Article
Text
id pubmed-9941525
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99415252023-02-22 A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma Song, Yan Zhang, Yue-yue Yu, Qin Chen, Tong Wei, Chao-gang Zhang, Rui Hu, Wei Qian, Xu-jun Zhu, Zhi Zhang, Xue-wu Shen, Jun-kang Front Oncol Oncology PURPOSE: Noninvasively assessing the tumor biology and microenvironment before treatment is greatly important, and glypican-3 (GPC-3) is a new-generation immunotherapy target for hepatocellular carcinoma (HCC). This study investigated the application value of a nomogram based on LI-RADS features, quantitative contrast-enhanced MRI parameters and clinical indicators in the noninvasive preoperative prediction of GPC-3 expression in HCC. METHODS AND MATERIALS: We retrospectively reviewed 127 patients with pathologically confirmed solitary HCC who underwent Gd-EOB-DTPA MRI examinations and related laboratory tests. Quantitative contrast-enhanced MRI parameters and clinical indicators were collected by an abdominal radiologist, and LI-RADS features were independently assessed and recorded by three trained intermediate- and senior-level radiologists. The pathological and immunohistochemical results of HCC were determined by two senior pathologists. All patients were divided into a training cohort (88 cases) and validation cohort (39 cases). Univariate analysis and multivariate logistic regression were performed to identify independent predictors of GPC-3 expression in HCC, and a nomogram model was established in the training cohort. The performance of the nomogram was assessed by the area under the receiver operating characteristic curve (AUC) and the calibration curve in the training cohort and validation cohort, respectively. RESULTS: Blood products in mass, nodule-in-nodule architecture, mosaic architecture, contrast enhancement ratio (CER), transition phase lesion-liver parenchyma signal ratio (TP-LNR), and serum ferritin (Fer) were independent predictors of GPC-3 expression, with odds ratios (ORs) of 5.437, 10.682, 5.477, 11.788, 0.028, and 1.005, respectively. Nomogram based on LI-RADS features (blood products in mass, nodule-in-nodule architecture and mosaic architecture), quantitative contrast-enhanced MRI parameters (CER and TP-LNR) and clinical indicators (Fer) for predicting GPC-3 expression in HCC was established successfully. The nomogram showed good discrimination (AUC of 0.925 in the training cohort and 0.908 in the validation cohort) and favorable calibration. The diagnostic sensitivity and specificity were 76.9% and 92.3% in the training cohort, 76.8% and 93.8% in the validation cohort respectively. CONCLUSION: The nomogram constructed from LI-RADS features, quantitative contrast-enhanced MRI parameters and clinical indicators has high application value, can accurately predict GPC-3 expression in HCC and may help noninvasively identify potential patients for GPC-3 immunotherapy. Frontiers Media S.A. 2023-02-07 /pmc/articles/PMC9941525/ /pubmed/36824129 http://dx.doi.org/10.3389/fonc.2023.1123141 Text en Copyright © 2023 Song, Zhang, Yu, Chen, Wei, Zhang, Hu, Qian, Zhu, Zhang and Shen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Song, Yan
Zhang, Yue-yue
Yu, Qin
Chen, Tong
Wei, Chao-gang
Zhang, Rui
Hu, Wei
Qian, Xu-jun
Zhu, Zhi
Zhang, Xue-wu
Shen, Jun-kang
A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma
title A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma
title_full A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma
title_fullStr A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma
title_full_unstemmed A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma
title_short A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma
title_sort nomogram based on li-rads features, clinical indicators and quantitative contrast-enhanced mri parameters for predicting glypican-3 expression in hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941525/
https://www.ncbi.nlm.nih.gov/pubmed/36824129
http://dx.doi.org/10.3389/fonc.2023.1123141
work_keys_str_mv AT songyan anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT zhangyueyue anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT yuqin anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT chentong anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT weichaogang anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT zhangrui anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT huwei anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT qianxujun anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT zhuzhi anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT zhangxuewu anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT shenjunkang anomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT songyan nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT zhangyueyue nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT yuqin nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT chentong nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT weichaogang nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT zhangrui nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT huwei nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT qianxujun nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT zhuzhi nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT zhangxuewu nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma
AT shenjunkang nomogrambasedonliradsfeaturesclinicalindicatorsandquantitativecontrastenhancedmriparametersforpredictingglypican3expressioninhepatocellularcarcinoma